No connection

Search Results

ABBV vs ACLX

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ACLX
Arcellx, Inc.
BEARISH
Price
$114.39
Market Cap
$6.69B
Sector
Healthcare
AI Confidence
88%

Valuation

P/E Ratio
ABBV
163.63
ACLX
--
Forward P/E
ABBV
15.42
ACLX
-71.6
P/B Ratio
ABBV
-146.66
ACLX
16.47
P/S Ratio
ABBV
6.5
ACLX
300.17
EV/EBITDA
ABBV
15.27
ACLX
-25.53

Profitability

Gross Margin
ABBV
71.46%
ACLX
0.0%
Operating Margin
ABBV
35.5%
ACLX
-3850.24%
Profit Margin
ABBV
4.0%
ACLX
0.0%
ROE
ABBV
137.96%
ACLX
-53.42%
ROA
ABBV
9.59%
ACLX
-24.05%

Growth

Revenue Growth
ABBV
9.1%
ACLX
-89.2%
Earnings Growth
ABBV
-88.7%
ACLX
--

Financial Health

Debt/Equity
ABBV
--
ACLX
0.13
Current Ratio
ABBV
0.72
ACLX
4.43
Quick Ratio
ABBV
0.47
ACLX
4.32

Dividends

Dividend Yield
ABBV
3.05%
ACLX
--
Payout Ratio
ABBV
490.15%
ACLX
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ACLX BEARISH

ACLX exhibits severe financial distress despite a strong technical trend and recent insider selling. The Piotroski F-Score of 1/9 indicates extremely weak financial health, with negative profitability metrics across all dimensions—operating margin at -3850.24%, ROE at -53.42%, and a revenue decline of -89.20% YoY. The absence of an Altman Z-Score raises bankruptcy risk concerns, while the Graham Number and intrinsic value are unavailable, suggesting no reliable defensive valuation. The stock trades at a massive premium with a Price/Sales of 300.17 and Forward P/E of -71.60, reflecting speculative growth expectations rather than fundamentals.

Strengths
Strong technical trend (10/100) indicating short-term bullish momentum
Recent quarters have shown positive earnings surprises (e.g., +69.5%, +184.0%)
High insider activity in recent quarters (though all sales)
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative operating margin (-3850.24%) and zero profit margin indicate unsustainable business model
Revenue declined 89.20% YoY, signaling core business contraction

Compare Another Pair

ABBV vs ACLX: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Arcellx, Inc. (ACLX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile